Notice: This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TOCA vs. MRVI, AUPH, ELVN, ARQT, ARDX, INVA, RCKT, CALT, ANIP, and GYREShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Maravai LifeSciences (MRVI), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), Arcutis Biotherapeutics (ARQT), Ardelyx (ARDX), Innoviva (INVA), Rocket Pharmaceuticals (RCKT), Calliditas Therapeutics AB (publ) (CALT), ANI Pharmaceuticals (ANIP), and Gyre Therapeutics (GYRE). These companies are all part of the "medical" sector. Tocagen vs. Maravai LifeSciences Aurinia Pharmaceuticals Enliven Therapeutics Arcutis Biotherapeutics Ardelyx Innoviva Rocket Pharmaceuticals Calliditas Therapeutics AB (publ) ANI Pharmaceuticals Gyre Therapeutics Maravai LifeSciences (NASDAQ:MRVI) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Is MRVI or TOCA more profitable? Maravai LifeSciences has a net margin of -81.13% compared to Tocagen's net margin of -176,433.34%. Maravai LifeSciences' return on equity of -6.61% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-81.13% -6.61% -3.45% Tocagen -176,433.34%-327.74%-111.87% Does the media prefer MRVI or TOCA? In the previous week, Maravai LifeSciences had 6 more articles in the media than Tocagen. MarketBeat recorded 6 mentions for Maravai LifeSciences and 0 mentions for Tocagen. Maravai LifeSciences' average media sentiment score of 0.51 beat Tocagen's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Overall Sentiment Maravai LifeSciences Positive Tocagen Neutral Does the MarketBeat Community prefer MRVI or TOCA? Tocagen received 181 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 66.03% of users gave Tocagen an outperform vote while only 63.92% of users gave Maravai LifeSciences an outperform vote. CompanyUnderperformOutperformMaravai LifeSciencesOutperform Votes6263.92% Underperform Votes3536.08% TocagenOutperform Votes24366.03% Underperform Votes12533.97% Do institutionals and insiders hold more shares of MRVI or TOCA? 50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 21.4% of Tocagen shares are owned by institutional investors. 0.6% of Maravai LifeSciences shares are owned by insiders. Comparatively, 10.9% of Tocagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, MRVI or TOCA? Maravai LifeSciences has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Do analysts prefer MRVI or TOCA? Maravai LifeSciences currently has a consensus target price of $10.33, suggesting a potential upside of 108.33%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, research analysts clearly believe Maravai LifeSciences is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 0 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.55Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, MRVI or TOCA? Tocagen has lower revenue, but higher earnings than Maravai LifeSciences. Tocagen is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$288.95M4.33-$119.03M-$1.64-3.02Tocagen$40K8,102.56-$63.52M-$2.69-5.04 SummaryMaravai LifeSciences beats Tocagen on 13 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$324.10M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-5.725.5095.1214.22Price / Sales8,102.56375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book30.1110.276.976.37Net Income-$63.52M$153.22M$118.73M$225.56M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$13.55+128.5%N/A+2,678.9%$324.10M$40,000.00-5.7277Gap UpHigh Trading VolumeMRVIMaravai LifeSciences4.7625 of 5 stars$4.96+2.9%$10.33+108.3%-2.2%$1.25B$288.95M0.00580AUPHAurinia Pharmaceuticals1.6942 of 5 stars$8.66+5.1%$10.00+15.5%-10.8%$1.24B$175.51M-54.93300ELVNEnliven Therapeutics2.3747 of 5 stars$25.16-1.1%$37.00+47.1%+141.3%$1.23BN/A-13.3850ARQTArcutis Biotherapeutics1.7656 of 5 stars$10.47+2.8%$15.50+48.0%+391.8%$1.23B$59.61M0.00150ARDXArdelyx3.9209 of 5 stars$5.17+5.1%$10.42+101.5%+12.3%$1.22B$124.46M0.00267Short Interest ↑INVAInnoviva1.3021 of 5 stars$19.17+0.1%N/A+40.6%$1.20B$310.46M27.75112News CoverageRCKTRocket Pharmaceuticals4.4279 of 5 stars$13.14+0.8%$51.00+288.1%-40.8%$1.20BN/A-4.74240Analyst ForecastAnalyst RevisionCALTCalliditas Therapeutics AB (publ)0.2585 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Positive NewsANIPANI Pharmaceuticals4.3472 of 5 stars$56.31+2.2%$77.33+37.3%+7.4%$1.18B$486.82M0.00642Positive NewsGYREGyre Therapeutics0.4888 of 5 stars$12.14-6.0%N/A-12.1%$1.14B$113.45M0.0040 Related Companies and Tools Related Companies Maravai LifeSciences Alternatives Aurinia Pharmaceuticals Alternatives Enliven Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Ardelyx Alternatives Innoviva Alternatives Rocket Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives ANI Pharmaceuticals Alternatives Gyre Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TOCA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
